Abstract
Background
The study was designed to determine whether impaired antiplatelet response to clopidogrel but not to aspirin may be responsible for loss of pleiotropic effects of the drug.
Methods
Study included 34 consecutive patients with STEMI undergoing primary percutaneous coronary intervention (PCI) with stent implantation treated with aspirin (loading dose 300 mg followed by 75 mg/day) and clopidogrel (loading dose 600 mg followed by 75 mg/day). On the basis of Platelet Function Analyzer (PFA)-100 test which measured closure times (CT) in test with collagen/epinephrine (CEPI-CT) or collagen/adenosine diphosphate (CADP-CT) patients were stratified after 7 days from admission as full aspirin or clopidogrel responders (CEPI-CT or CADP-CT = 300 sec., respectively) and non-full aspirin or clopidogrel responders (CEPI-CT or CADP-CT < 300 sec., respectively). High sensitivity C-reactive protein (hs-CRP) was measured at baseline and after 7 days of treatment.
Results
All patients received comparable statin treatment. Median and interquartile ranges (IQR) of hs-CRP increased significantly from 2.5 mg/L (0.4–44.8) at baseline to 8.05 mg/L (1.4–33.9) at day 7 (P = .002) in non-full clopidogrel responders subgroup and only slightly in the full clopidogrel responders subgroup (2.45 mg/L, IQR 0.4–48.3 vs. 4.2 mg/L, IQR 1.9–17.5) (P = .3) remaining within reference intervals. On the contrary median and IQR of hs-CRP increased significantly in both non-full aspirin responders (2.4 mg/L, IQR 1.3–3.3 vs. 5.8 mg/L, IQR 3.2–14.8, P = .01) and full aspirin responders (2.9 mg/L, IQR 2.0–3.7 vs. 5.6 mg/L, IQR 4.3–12.9, P = .04).
Conclusions
Impaired antiplatelet response to clopidogrel but not to aspirin may contribute to smaller anti-inflammatory response in patients with ST-elevation myocardial infarction.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology (2005) Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European society of cardiology. Eur Heart J 26:804–847
Cattaneo M (2004) Aspirin and clopidogrel. Efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 24:1980–1987
Wang TH, Bhatt DL, Topol EJ (2006) Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 27:647–654
Nguyen TA, Diodati JG, Pharand C (2005) Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 45:1157–1164
Szczeklik A, Musial J, Undas A, Sanak M (2005) Aspirin resistance. J Thromb Haemost 9:2015–2021
Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ (2005) Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45:246–251
Chew DP, Bhatt DL, Robbins MA (2001) Effects of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 88:672–674
Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK (2001) Clopidogrel in Ustable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation [published corrections appear in N Engl J Med. 2001;345:1506 and 1716]. N Engl J Med 345:494–502
Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al (2006) Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 55:780–784
Ferreiros ER, Boissonnet CP, Pizarro R et al (1999) Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation 100:1958–1963
Toss H, Lindahl B, Siegbahn A, Wallentin L (1997) Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease Circulation 96:4204–4210
Heeschen C, Dimmeler S, Hamm CW et al (2003) CAPTURE Study Investigators. Soluble CD40 ligand in acute coronary syndromes N Engl J Med 348:1104–1111
Cermak J, Key NS, Bach RR, Balla J, Jacob HS, Vercellotti GM (1993) C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 82:513–520
Dibra A, Mehilli J, Braun S et al (2005) Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. Am Heart J 150:344–350
Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK (2006) The platelet physiology subcommittee of the scientific and standardization committee of the international society on thrombosis and haemostasis. Platelet function analyzer (PFA)-100® closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 4:312–319
Azar RR, Kassab R, Zoghbi A et al (2006) Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J 151:521.e1–521.e4
Acknowledgement
This study was a part of the Medical University of Warsaw scientific grant No 1WR/NM2/06.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Malek, L.A., Grabowski, M., Spiewak, M. et al. Relation between impaired antiplatelet response to clopidogrel and possible pleiotropic effects. J Thromb Thrombolysis 24, 301–305 (2007). https://doi.org/10.1007/s11239-007-0026-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-007-0026-8